Rojer R A, Mulder N H, Nieweg H O
Am J Med. 1978 Oct;65(4):655-60. doi: 10.1016/0002-9343(78)90854-9.
Eleven of 14 patients with primary myelofibrosis were given a therapeutic trial with 250 mg of pyridoxine hydrochloride daily because of refractory anemia. The effect on the hemoglobin level and the hematocrit value was studied and compared to that in a group of untreated patients with the same degree of anemia. Six of 11 treated patients responded within three months with a rise in the hemoglobin level (at least 3 g/100 ml) and/or an increase in the hematocrit value (at least 10 per cent), and transfusions were no longer required. Deliberate discontinuation of pyridoxine treatment in one responding patient was followed by a relapse of the anemia; resumption of therapy once again induced an erythropoietic response. Spontaneous remissions of anemia were not observed in the untreated group. It is concluded that a trial with pyridoxine is warranted in patients with myelofibrosis and refractory anemia.
14例原发性骨髓纤维化患者中有11例因难治性贫血接受了每日250毫克盐酸吡哆醇的治疗试验。研究了其对血红蛋白水平和血细胞比容值的影响，并与一组贫血程度相同的未治疗患者进行了比较。11例接受治疗的患者中有6例在三个月内有反应，血红蛋白水平升高（至少3克/100毫升）和/或血细胞比容值增加（至少10%），不再需要输血。一名有反应的患者故意停用吡哆醇治疗后，贫血复发；再次恢复治疗再次诱导了红细胞生成反应。未治疗组未观察到贫血的自发缓解。结论是，对骨髓纤维化和难治性贫血患者进行吡哆醇试验是有必要的。
